Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity

Pharmacokinetics, Safety, and Efficacy of Fisetin - A Phase I and Pilot Phase IIa Study

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06431932

Acronym

Fisetin HIGH

Enrollment

Registered

2024-05-29

Start date

2026-03-24

Completion date

2028-12-31

Last updated

2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Multimorbidity

Keywords

Senolytic, Pharmacokinetics, Chronic inflammation

Brief summary

The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models. We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.

Detailed description

The goal of this pilot trial is to conduct a controlled clinical study to gather data on the pharmacokinetic profile of fisetin and its metabolites and on the safety and tolerability of fisetin in healthy volunteers as well as in older medical patients. Furthermore, we aim to identify potential outcome measures and perform sample size calculations for these outcomes, with the intent to conduct a larger scale effect study, at later date, given the result from this pilot study suggests that this would be feasible and safe. The trial consists of: * a single-arm open-label study, in which healthy volunteers (n=20) will receive fisetin corresponding to 20 mg/kg/day for two consecutive days. * a 2-arm triple-blind randomized placebo-controlled study, in which older medical patients (n=40) will receive either: * 20 mg/kg/day fisetin for two consecutive days, or * placebo for two consecutive days. Each of the studies (open-label study and randomized placebo-controlled study) consists of three sub-studies: * Sub-study I aims to investigate the pharmacokinetic properties of fisetin and its main metabolites following oral administration at a dose of 20 mg/kg/day in healthy volunteers and in older medical patients. * Sub-study II aims to assess the safety and tolerability of oral treatment with fisetin at a dose of 20 mg/kg/day fisetin for two consecutive days in healthy volunteers and in older medical patients. * Sub-study III aims to gather representative measurements to assess the utility of inflammation, SASP, senescence, senolysis, and aging biomarkers, as well as measures of frailty, clinical parameters, physical and cognitive function, and quality of life as potential outcomes in future clinical trials; additionally, to perform sample size calculations for future trials based on these data.

Interventions

DRUGFisetin

Subjects will receive fisetin corresponding to 20 mg/kg/day for two consecutive days.

DRUGPlacebo

Subjects will receive a corresponding number of placebo capsules for two consecutive days.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

The trial consists of: * a single-arm open-label study, in which healthy volunteers (n=20) will receive fisetin corresponding to 20 mg/kg/day for two consecutive days. * a 2-arm triple-blind randomized placebo-controlled study, in which older patients with multimorbidity (n=40) will receive either: * 20 mg/kg/day fisetin for two consecutive days, or * placebo for two consecutive days.

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Healthy volunteers: Inclusion Criteria: * Aged 20-35 years * suPAR levels \<3.5 ng/mL (± 15% corresponding to assay variation) * Able to cooperate cognitively * Able to read and understand Danish * Women of childbearing potential must use effective contraception

Exclusion criteria

* Body weight \>100 kg * Inability to swallow pills * Pregnant and/or lactating * Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules * Presence of any condition that the investigator believes would put the subject at risk or would preclude the participant from successfully completing all aspects of the trial * Presence of known chronic diagnosis * Active acute illness * Prescribed medication, except contraceptives * Previous cancer diagnosis or treatment * Use of senolytic and other "anti-aging" supplements Older patients with multimorbidity: Inclusion Criteria: At screening #1 during hospital admission: * Acutely hospitalized medical patient * Age ≥65 years * suPAR \>5 ng/mL (± 15% corresponding to assay variation) * Multimorbidity (≥2 chronic diagnoses) * Able to cooperate cognitively * Able to read and understand Danish At screening #2 28 days after hospital discharge: * suPAR \>5 ng/mL (± 15% corresponding to assay variation)

Design outcomes

Primary

Measure	Time frame	Description
Population-based pharmacokinetic model for fisetin and metabolites	24 hours	To develop a population-based pharmacokinetic (popPK) model for fisetin and its main metabolites in healthy volunteers and older patients, covariates such as body weight, body composition, age, and CYP inducers/inhibitors will be tested for influence on interindividual variability.
Adverse events	Day 1 to 3	Number of participants to experience adverse events
suPAR	Day 1 to 29	The change in plasma levels of suPAR and a sample size calculation based on these data.

Secondary

Measure	Time frame	Description
Population-based PKPD model for fisetin	24 hours	Changes in any of the measured biomarkers and the relationship between the pharmacokinetics and pharmacodynamics of fisetin will be investigated using population PKPD modeling.
Renal excretion of fisetin and its main metabolites	24 hours	Urinary levels of fisetin and its main metabolites
Symptoms and adverse events	Day 1 to 3	Number of participants to experience symptoms and clinically significant changes in vital signs (i.e., blood pressure, pulse).
SASP factors and inflammation markers	Healthy volunteers: day 1, 2, 29. Older patients: day 1, 2, 8, 15, 29, 57, 84.	The change in plasma levels of SASP factors and inflammation markers (e.g., cytokines, chemokines, proteases, growth factors).
Senescence	Healthy volunteers: day 1, 29. Older patients: day 1, 8, 15, 29, 84.	The change in expression levels of senescence markers (e.g., p16INK4a, p21CIP1/WAF1, SA-B-gal) in immune cells and tissue biopsies (skin and adipose tissue).
Senolysis	Healthy volunteers: day 1, 2, 29. Older patients: day 1, 2, 8, 15, 29, 84.	The change in expression levels of senolysis markers (e.g., leukotriene B4, dihomo-15d-PGJ2 (oxylipin or 1a,1b-dihomo-15-deoxy-D12,14-prostaglandin J2), and 15-Deoxy-delta 12, 14-prostaglandin J2).
Aging markers	Healthy volunteers: day 1, 2, 29. Older patients: day 1, 2, 8, 15, 29, 57, 84.	The change in plasma levels of aging markers (e.g., α-klotho, fibroblast growth factor 21).
Clinical markers	Healthy volunteers: day 1, 2, 29. Older patients: day 1, 2, 8, 15, 29, 57, 84.	The change in levels of routine biochemistry markers (e.g., alanine aminotransferase, albumin, alkaline phosphatase, bilirubin, blood urea nitrogen, coagulation factors II, VII and X and International Normalized Ratio, CRP, creatinine, hemoglobin, lactate dehydrogenase, mean corpuscular hemoglobin concentration, mean corpuscular volume, neutrophils, potassium, sodium, thrombocytes, white blood cell count, cholesterol (total, low-density lipoproteins, high-density lipoproteins), triglycerides, and hemoglobin A1c).
Frailty Index OutRef	Healthy volunteers: day 1, 29. Older patients: day 1, 2, 8, 15, 29, 57, 84.	The change in frailty status calculated as Frailty Index OutREF (FI-OutRef).
Frailty Index	Healthy volunteers: day 1, 29. Older patients: day 1, 2, 8, 15, 29, 57, 84.	The change in frailty status calculated using a modified version of Fried frailty criteria.
Physical function	Healthy volunteers: day 1, 29. Older patients: day 1, 29, 84.	The change in physical function (e.g., gait speed, hand grip strength, chair stand test, balance).
Cognitive function (Montreal Cogntive Assessment)	Healthy volunteers: day 1, 29. Older patients: day 1, 29, 84.	The change in cognitive function assessed using the MoCA score (0-30 with higher scores representing better cognitive function).
Cognitive function (Digit Symbol Substitution Test)	Healthy volunteers: day 1, 29. Older patients: day 1, 29, 84.	The change in cognitive function assessed using the Digit Symbol Substitution Test (number of correct symbols).
Quality of life	Healthy volunteers: day 1, 29. Older patients: day 1, 29, 84.	The change in quality of life assessed using the EuroQol-5D-5L (index value and VAS scale 0-100; with higher scores representing better quality of life).
Self-rated health	Healthy volunteers: day 1, 29. Older patients: day 1, 29, 84.	The change in self-rated health (score 1-5; 1:"excellent", 2:"very good", 3:"good", 4:"fair", or 5:"bad").

Countries

Denmark

Contacts

CONTACTJuliette Tavenier

juliette.tavenier@regionh.dk+4538620640

CONTACTLine Jee Hartmann Rasmussen

line.jee.hartmann.rasmussen@regionh.dk+4538620640

STUDY_CHAIRJuliette Tavenier